Detalhe da pesquisa
1.
Higher concentrations of kynurenic acid in CSF are associated with the slower clinical progression of Alzheimer's disease.
Alzheimers Dement
; 19(12): 5573-5582, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37264981
2.
Neuropsychiatric symptoms and comorbidity: Associations with dementia progression rate in a memory clinic cohort.
Int J Geriatr Psychiatry
; 36(6): 960-969, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33462872
3.
Trajectories and risk factors of dementia progression: a memory clinic cohort followed up to 3 years from diagnosis.
Int Psychogeriatr
; 33(8): 779-789, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33213607
4.
Regional MRI volumetry using NeuroQuant versus visual rating scales in patients with cognitive impairment and dementia.
Brain Behav
; 14(2): e3397, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38600026
5.
Diagnostic accuracy of brain age prediction in a memory clinic population and comparison with clinically available volumetric measures.
Sci Rep
; 13(1): 14957, 2023 09 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37696909
6.
Trajectories of occupational physical activity and risk of later-life mild cognitive impairment and dementia: the HUNT4 70+ study.
Lancet Reg Health Eur
; 34: 100721, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37927437
7.
Is Amyloid Burden Measured by 18F-Flutemetamol PET Associated with Progression in Clinical Alzheimer's Disease?
J Alzheimers Dis
; 85(1): 197-205, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-34776444
8.
Evaluation of semi-quantitative measures of 18F-flutemetamol PET for the clinical diagnosis of Alzheimer's disease.
Quant Imaging Med Surg
; 12(1): 493-509, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34993096
9.
Associations of cerebrospinal fluid amyloidogenic nanoplaques with cytokines in Alzheimer's disease.
Transl Neurodegener
; 10(1): 18, 2021 06 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34099032
10.
Time from dementia diagnosis to nursing-home admission and death among persons with dementia: A multistate survival analysis.
PLoS One
; 15(12): e0243513, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33275638
11.
Comparison of Cerebrospinal Fluid Amyloidogenic Nanoplaques With Core Biomarkers of Alzheimer's Disease.
Front Aging Neurosci
; 12: 608628, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33488383
12.
A high cerebrospinal fluid soluble TREM2 level is associated with slow clinical progression of Alzheimer's disease.
Alzheimers Dement (Amst)
; 12(1): e12128, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33313376
13.
Amyloidogenic Nanoplaques in Cerebrospinal Fluid: Relationship to Amyloid Brain Uptake and Clinical Alzheimer's Disease in a Memory Clinic Cohort.
J Alzheimers Dis
; 77(2): 831-842, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32741818
14.
Amyloid-ß PET-Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer´s disease diagnosis in a memory clinic.
PLoS One
; 14(8): e0221365, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31430334
15.
Survival and years of life lost in various aetiologies of dementia, mild cognitive impairment (MCI) and subjective cognitive decline (SCD) in Norway.
PLoS One
; 13(9): e0204436, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30240425